Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo
Scientific Editors:George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)Commenting Expert:Michael Untch, HELIOS Klinikum, Berlin
In this edition Peter Goodwin and Sara Freeman report from:
European Breast Cancer Conference, Berlin, April 15-19, 2008;
Chemotherapy Foundation Symposium, November 6-10, 2007, New York;
9th European Congress: Perspectives in Lung Cancer, Turin, March 14-15, 2008;
The Lancet, New England Journal of Medicine
Myron Czuczman
In this edition:
1. Lymphoma Immunotherapy: Anti-CD-80 Therapy With Galiximab
Myron Czuczman, Roswell Park Cancer Institute, Buffalo NYChemotherapy Foundation
2. Esophagogastric Cancer: Capecitabine First Line?
George Canellos, Dana-Farber Cancer Institute, BostonN Engl J Med 358:1
3. Mammography: As Good For Older Patients
Jacques Fracheboud, Erasmus Medical Center, RotterdamEBCC , Berlin
4. Mammography: Three Year Interval Justified
Roger Blamey, Nottingham City Hospital
5. Mammography Assessed
Michael Untch, HELIOS Klinikum, Berlin
6. Colorectal Cancer: Add Chemo To Liver Mets Resection?
George Canellos, Dana-Farber Cancer Institute, BostonLancet 371:1007
7. Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
Christian Manegold, Heidelberg University Medical Center, Manheim andNick Thatcher, Christie Hospital, ManchesterEuropean Lung Cancer Congress, Turin
8. Smoking And Death in India
George Canellos, Dana-Farber Cancer Institute, BostonN Engl J Med 358:1137
Buy Audio Journal of Oncology Digital CopyOrder Audio Journal of Oncology CDLISTEN
Tags
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Juan Du MD PhD, ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma
Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.
Gaorav Gupta MD PhD; SABCS 2025: Pre-Op Radiation Improved T-cell Infiltration in Hormone Receptor-positive, HER2-negative Invasive Breast Cancer; Could Boost Systemic Therapy Responses
At SABCS 2025, Gaorav Gupta MD PhD presented findings from the TBCRC-053 (P-RAD) study. The research showed that pre-operative radiation therapy significantly increased T-cell infiltration in hormone receptor-positive, HER2-negative invasive breast cancer. This novel approach could enhance anti-tumor immunity and boost responses to systemic therapies like immunotherapy and chemotherapy in this common breast cancer subtype.